Jesús F. San Miguel
YOU?
Author Swipe
View article: Table S4 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel
Table S4 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel Open
HR and P values for landmark PFS within first year
View article: Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network
Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network Open
The treatment landscape of heavily pretreated relapsed/refractory MM has changed considerably in recent years with the introduction of novel BCMA‐ and GPRC5D‐directed immunotherapies, including CAR T‐cell therapy, bispecific antibodies (Bs…
View article: Enfermedad medible residual en hematología: un objetivo terapéutico
Enfermedad medible residual en hematología: un objetivo terapéutico Open
View article: Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN–HARMONY Alliance platform
Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN–HARMONY Alliance platform Open
Traditional risk stratification in multiple myeloma (MM) relies on clinical and cytogenetic parameters but has limited predictive accuracy. Machine learning (ML) offers a novel approach by leveraging large datasets and complex variable int…
View article: Myeloma: a sky full of MRD stars
Myeloma: a sky full of MRD stars Open
View article: Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma Network
Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma Network Open
Venous thromboembolism (VTE) is a frequent complication in patients with multiple myeloma (MM) that leads to increased morbidity, mortality, treatment interruptions, and reduced quality of life. Αn Expert Panel Consensus Guideline on behal…
View article: Talquetamab improves patient‐reported symptoms and health‐related quality of life in relapsed or refractory multiple myeloma: Results from the phase 1/2 MonumenTAL‐1 study
Talquetamab improves patient‐reported symptoms and health‐related quality of life in relapsed or refractory multiple myeloma: Results from the phase 1/2 MonumenTAL‐1 study Open
Background Talquetamab is the first approved G protein–coupled receptor family C group 5 member D–targeting bispecific antibody for the treatment of triple‐class exposed relapsed/refractory multiple myeloma (RRMM) on the basis of results f…
View article: EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma
EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma Open
View article: Enhanced Risk Stratification of Smoldering Multiple Myeloma with Dynamic Biomarkers: A Multinational, Multicenter Study including 2,270 Participants (PANGEA 2.0)
Enhanced Risk Stratification of Smoldering Multiple Myeloma with Dynamic Biomarkers: A Multinational, Multicenter Study including 2,270 Participants (PANGEA 2.0) Open
View article: Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment
Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment Open
The continuous improvement in progression-free survival (PFS) of patients with multiple myeloma (MM) raises interest in evaluating peripheral residual disease (PRD) toward more frequent readouts of tumor kinetics while preserving quality o…
View article: Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Comparison
Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Comparison Open
View article: Supplemental Table 9 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma
Supplemental Table 9 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma Open
Clinical characteristics of MM patients who develop SPM (n = 29) vs those who have not (n = 279). P-value is calculated using corrected χ2 for dichotomous variables, and Kruskal-Wallis for numerical variables.
View article: Supplemental Table 4 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma
Supplemental Table 4 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma Open
Detected variants passing all filters categorized as pathogenic or likely pathogenic somatic mutations.
View article: Supplemental Table 3 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma
Supplemental Table 3 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma Open
Genetic relationship between mutant HPC and tumor cells.
View article: Supplemental Table 1 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma
Supplemental Table 1 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma Open
Key disease characteristics between patients with available (n = 308) and unavailable (n = 583) samples included and not included in this study from the GEM2012MENOS65, GEM-CESAR, and GEM-CLARIDEX trials. P-value is calculated using correc…
View article: Supplemental Table 5 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma
Supplemental Table 5 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma Open
Quality control of the 555 NGS samples included in the study.
View article: Supplemental Table 2 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma
Supplemental Table 2 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma Open
List of genes included in the pan-myeloid targeted sequencing panel (SOPHiA GENETICS, Saint Sulpice, Switzerland).
View article: Supplemental Table 8 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma
Supplemental Table 8 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma Open
Hematologic toxicity during treatment observed in patients enrolled in the GEM2012MENOS65, GEM-CLARIDEX and GEM-CESAR clinical trials compared to mutant HPC detected at baseline. P-value is calculated using corrected χ2 test.
View article: Supplemental Figure 3 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma
Supplemental Figure 3 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma Open
Overall survival (OS) according to the top four frequently mutated genes at diagnosis: (A) DNMT3A, (B) TET2, (C) ASXL1, and (D) STAG2 in untreated patients enrolled in the GEM2012MENOS65 and GEM- CLARIDEX trials with BM HPC samples.
View article: Supplemental Figure 2 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma
Supplemental Figure 2 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma Open
Genetic relationship between mutant HPC and tumor cells. Concordance between the mutational landscape of hematopoietic progenitor cells (HPC) and patient-paired tumor cells (n = 42) used as filtering criteria for mutations observed in RAS …
View article: Supplemental Table 7 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma
Supplemental Table 7 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma Open
Clinical and tumor microenvironmental characteristics of untreated, newly diagnosed active MM patients having normal (n = 129) vs mutant HPC (n = 38). P-value is calculated using corrected χ2 for dichotomous variables, and Krusk…
View article: Supplemental Figure 1 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma
Supplemental Figure 1 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma Open
Overview illustrating a graphical representation of gating strategy used to detect bone marrow CD34+ hematopoietic progenitor cells (HPC) and plasma cells (PCs) using fluorescence activated cell sorting (BD FACSDiva v 8.0.2). Panels show b…
View article: Supplemental Table 6 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma
Supplemental Table 6 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma Open
Mutational landscape of HPC according to a variant allele frequency (VAF) ≥2% among untreated patients with MM. Frequencies are calculated according to all patients with BM HPC at diagnosis (n = 232).
View article: Data from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma
Data from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma Open
Mutant hematopoietic progenitor cells (HPC) may expand under high-dose melphalan- and lenalidomide-based regimens and give rise to hematologic second primary malignancies (SPM) in multiple myeloma. To determine whether genetic screening of…
View article: Single-Cell Multiomics Reveals Regulatory Mechanisms of CAR T Cell Persistence and Dysfunction in Multiple Myeloma
Single-Cell Multiomics Reveals Regulatory Mechanisms of CAR T Cell Persistence and Dysfunction in Multiple Myeloma Open
Understanding the mechanisms that drive chimeric antigen receptor (CAR) T cell function and persistence in multiple myeloma (MM) remains a critical challenge for improving therapeutic outcomes. In this study, we applied single-cell multiom…
View article: High‐risk features of early relapse in newly‐diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy
High‐risk features of early relapse in newly‐diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy Open
Patients with newly‐diagnosed multiple myeloma (MM) who experience early relapse (ER) have dismal overall survival (OS). Their prospective identification, either before or soon after treatment initiation, is paramount to use alternative ap…
View article: Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study
Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study Open
Janssen.
View article: Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma Open
PURPOSE Survival for patients with multiple myeloma (MM) has improved but outcomes remain heterogeneous. Consistent diagnostic identification of high-risk disease is desirable to address unmet patient need. The aim was to investigate the c…
View article: European Myeloma Network Group review and consensus statement on primary plasma cell leukemia
European Myeloma Network Group review and consensus statement on primary plasma cell leukemia Open
View article: A plain language summary of the ICARIA study, comparing isatuximab–pomalidomide– dexamethasone with pomalidomide– dexamethasone in people with multiple myeloma
A plain language summary of the ICARIA study, comparing isatuximab–pomalidomide– dexamethasone with pomalidomide– dexamethasone in people with multiple myeloma Open
International audience